Treatment of Mild, Moderate, and Severe Lupus Erythematosus: Focus on New Therapies Authors
First Online: 17 May 2011 DOI:
10.1007/s11926-011-0186-6 Cite this article as: Dall’Era, M. & Chakravarty, E.F. Curr Rheumatol Rep (2011) 13: 308. doi:10.1007/s11926-011-0186-6
Despite large-scale efforts devoted to the conduct of clinical trials in systemic lupus erythematosus (SLE), no new therapy has been approved for treatment of this disease in more than 50 years. Increased understanding of the immunologic mechanisms underlying SLE has led to the development of a variety of biologic agents that target specific aspects of the adaptive and innate arms of the immune system, including B cells, T cells, dendritic cells, and various cytokines. One of these agents, belimumab, was the subject of two positive phase 3 trials in nonrenal lupus that have given us hope that a new therapy for SLE may be finally within our grasp. In addition to these newer therapies, recent studies of standard-of-care medications such as mycophenolate mofetil and hydroxychloroquine have better defined the efficacy and safety of these agents for the treatment of lupus nephritis and nonrenal lupus. This article provides a discussion of several novel biologic agents at different stages of development for the treatment of SLE, as well as an analysis of newer data on agents that have been used in the treatment of SLE for many years.
Systemic lupus erythematosus
References Papers of particular interest, published recently, have been highlighted as: •• Of major importance
•• Mackay F, Figgett WA, Saulep D, et al. B-cell stage and context-dependent requirements for survival signals from BAFF to the B-cell receptor. Immunol Rev 2010, 237:205–25.
This is a very detailed review of the role of BAFF in B-cell development, survival, and activation.
Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003;48:1484–92.
Merrill JT, Newelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum. 2010;62:222–33.
Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 2009;60:S429 [abstract 1149].
Terrier B, Amoura A, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity to Rituximab Registry. Arthritis Rheum. 2010;62:2458–66.
Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first 50 patients. Arthritis Care Res. 2009;61:482–7.
Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patient with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28:468–76.
•• Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010, 29: 707–16.
This is a systematic review of results of off-label use of rituximab for autoimmune disease.
Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis. 2008;67 Suppl 3:iii64–5.
Furie RA, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R109.
Wallace DJ, Stohl W, Furie RA, et al. A phase II randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168–78.
Navarra S, Guzman R, Gallacher A, et al. Belimumab, a BLys-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. American College of Rheumatology 2009 Annual Scientific Meeting: Philadelphia, PA (17–21 October, 2009)
Furie RA, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through week 76. American College of Rheumatology 2010 Annual Scientific Meeting: Atlanta, GA (6–10 November, 2010)
Merrill JT, Wallace DJ, Furie RA, et al. Five-year experience with belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE). American College of Rheumatology 2010 Annual Scientific Meeting: Atlanta, GA (6–10 November, 2010)
Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74–85.
Wallace DJ, Kalunian KC, Petri MA, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Arthritis Rheum. 2010;62:S605 [Abstract 1452].
Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56:4142–50.
Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus. Arthritis Rheum. 2010;62:3077–87.
•• Crow MK. Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin N Am 2010, 36: 173–86.
This is an outstanding overview of the immunobiology of IFN-α and its role in autoimmune diseases.
Niewold TN, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulemic vasculitis associated with hepatitis C. Clin Rheumatol. 2005;24:178–81.
Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301:5–8.
Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36:481–90.
Niewold TB, Clark DN, Salloum R, et al. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:948364.
Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785–96.
McBride JM, Morimoto A, Drappa J. Genentech’s rontalizumab is well-tolerated by lupus patients in a phase I clinical trial. Lupus Foundation of America Website, accessed 11/28/2010. Available at
Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156–62.
Chan TM, Tse KC, Tang CS, et al. Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076–84.
Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219–28.
Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.
Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology. 2010;49:128–40.
Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152–60.
Wofsy D, et al. Aspreva lupus management study maintenance results. Lupus 2010; 19 (Abstr. Suppl): 27 (Abstract CS12.5)
Houssiau FA, D’Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 2010 (Epub ahead of print)
The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150–4.
The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus. 1998;7:80–5.
Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum. 2006;54:3068–70.
Wallace DJ. Antimalarial therapies. In: Wallace D, Hahn B, editors. Dubois’ lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1152–74.
Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202:1131–9.
•• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69: 20–8.
This is a comprehensive, systematic review of the role of antimalarials in disease activity, damage, and toxicity related to SLE.
Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775–84.
•• Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/LA antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010:69: 1827–30.
This was an expertly performed study combining outcomes of three cohorts of infants born to mothers with SLE and anti-SSA/SSB antibodies.
PubMed CrossRef Copyright information
© Springer Science+Business Media, LLC 2011